MyoKardia's mission is to revolutionize the treatment of genetic cardiomyopathies and related heart disease through exploiting advances in sarcomere-related biochemistry and molecular biology.
MyoKardia is developing a pipeline of novel, small molecule therapeutics that address key clinical needs for patients with genetic heart disease.Learn More
News & Events
MyoKardia Announces Launch of SHaRe Patient Registry for Genetic Heart Disease in Collaboration with World-Leading Cardiovascular Patient Care Centers
MyoKardia Appoints Biotech Veteran Mark L. Perry to Board of Directors
MyoKardia Appoints Tassos Gianakakos to Chief Executive Officer
MyoKardia Appoints Industry Veteran Jonathan Fox, M.D., Ph.D.,as Chief Medical Officer